多西他赛联合奥沙利铂一线治疗晚期或复发胃癌的疗效观察  

Combination therapy with docetaxel and oxaliplatin as a first-line treatment in patients with advanced or recurrent gastric cancer

作　　者：唐三元[1] 殷耒兰 陈琳[1] 苏菊[1] 黄卫国[2] 李跃华[1] 伍小平[1] 朱红波[1] 

机构地区：[1]南华大学附属第一医院肿瘤内科,湖南衡阳421001 [2]南华大学肿瘤研究所

出　　处：《中国现代医药杂志》2013年第4期10-11,共2页Modern Medicine Journal of China

摘　　要：目的评价多西他赛和奥沙利铂联合治疗晚期或复发胃癌的疗效和毒副作用。方法入组25例晚期或复发胃癌患者。用多西他赛75mg/m2,第1d;奥沙利铂,130mg/m2,第2d,21d为1周期。结果 25例患者可评价疗效。总有效率为52.0%(13/25),疾病控制率为96.0%(24/25)。中位疾病进展时间(TTP)和总生存期(OS)分别是6.8月和14.1月。主要的毒性反应是白细胞减少、中性白细胞减少、恶心、呕吐、脱发和感觉神经病,以Ⅰ～Ⅱ度为主。结论多西他赛联合奥沙利铂一线治疗晚期或复发胃癌有较好的临床疗效和可接受的毒性。Objective To evaluate the efficacy and toxicities of combination therapy with docetaxel and oxaliplatin in patients with advanced or recurrent gastric cancer. Methods Twenty-five patients with advanced or recurrent gastric cancer were enrolled. Patients received docetaxel, 75mg/m2, on day 1 and oxaliplatin, 130mg/m2 on day 2 every 3 weeks. Results All 25 patients were assessable for response. The overall response rate was 52.0% （13/25） and the disease control rate was 96.0% （24/25）. Median time to progression （TrP） and overall survival （OS） were 6.8 months and 14.1 months, respectively. The major toxicities were leukopenia, neutropenia, nausea,vomit, alopecia and sensory neuropathy. The main toxicity was grade 1 to 2. Conclusion The combination of docetaxel and oxaliplatin have good clinical activity with acceptable toxicity in patients with advanced or recurrent gastric cancer.

关 键 词：晚期胃癌 多西他赛 奥沙利铂 疗效 毒性反应 

分 类 号：R735.2[医药卫生—肿瘤]